Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Which Crypto Should Newbies Buy First guides you to practical, beginner-friendly first purchases.
27,491 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Ready to secure your retirement with a solid plan? This 10-year roadmap shows you how to build retirement income plan...
Nvidia's upcoming earnings could be the turning point for AI stocks. This article breaks down what to watch, possible...
A coalition of fair housing and economic justice groups filed a federal lawsuit in Washington, D.C., challenging a Re...
A fresh AI-driven rally has investors buzzing about Alphabet. This article breaks down why alphabet stock popped toda...
Oil prices tumbled to their lowest levels since early March as a tentative Iran agreement raised hopes of easing tank...
The relationship between OpenAI and Microsoft once looked like a straightforward path to AI profits. Today, smart mon...
Public moments can shift finances as quickly as headlines change. This article uses adele’s rare return sparks as a s...
Micron has surged into a market-defining position as traders weigh earnings potential against memory-price risk. Anal...
Institutional moves shape the AI stock landscape. This article dives into Philippe Laffont’s Coatue strategy, why Nvi...
Broadcom is set to report Q1 FY2026 after the close as investors weigh AI-driven demand and margins. This live earnin...
Oil breaks $100 again as Middle East tensions flare, lifting energy stocks and reshaping risk-on bets for 2026. Inves...